Inclisiran-mediated reductions in Lp(a) in the ORION-1 trial

31 August 2019 (00:00 - 00:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor David Kallend

The Medicines Company, Zurich (Switzerland)

9 More presentations in this session

Presentation thumbnail

Remnant cholesterol increases the risk for recurrent vascular events independent of ldl-cholesterol in patients with clinical manifest vascular disease.

Ms B. Heidemann (Utrecht, NL)

Abstract Slides Video

Presentation thumbnail

The contribution of familial hypercholesterolemia (FH) to premature coronary artery disease decreased by 2-fold between 1998 and 2018 in a founder population with high prevalence of FH

Doctor A. Lauziere (Chicoutimi, CA)

Abstract Slides Video

Presentation thumbnail

The effects of climate and air pollutants on heart failure hospitalizations and mortality (CLIMATE-HF Study)

Doctor W. Ngampongpan (Bangkok, TH)

Abstract Slides Video

Presentation thumbnail

Association between secondhand smoke exposure and diabetes mellitus in 131,724 Korean never smokers using self-reported questionnaire and cotinine: gender differences

Doctor J. Kim (Seoul, KR)

Abstract Slides Video

Presentation thumbnail

Irregular eating behavior and incidence of cardiovascular disease: results from a swedish 60-year-old cohort of men and women.

Doctor F. Laguzzi (Stockholm, SE)

Abstract Slides Video

Access the full session

Session thumbnail

Lipids / Cardiovascular risk prediction / Life style

The Event

ESC Congress 2019

31 August - 4 September 2019

You may be interested in

Congress Presentation

Lipid control in cardiovascular patients

Congress Presentation

Fix the plaque, fight the lipids: why low-density lipoproteins still matter after percutaneous coronary intervention

Congress Presentation

What’s new in LDL lowering?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources